Clinical features of spinal muscular atrophy (SMA) type 2

被引:0
|
作者
Cances, C. [1 ]
Richelme, C. [2 ]
Barnerias, C. [3 ]
Espil, C. [4 ]
机构
[1] Toulouse Univ Hosp, Neuropaediat Dept, AOC Atlantique Occitante Caraibe Reference Ctr Ne, Toulouse, France
[2] Hop Pediat Nice CHU Lenval, CMR Neuromusculaire PACARARE, Nice, France
[3] CMR Neuromusculaire NEIDF, AP HP, Paris, France
[4] CHU Bordeaux, Hop Enfants, CMR Neuromusculaire AOC, Bordeaux, France
来源
ARCHIVES DE PEDIATRIE | 2020年 / 27卷 / 07期
关键词
Spinal muscular atrophy type 2; Diagnosis semiology; Clinical evolution; PROSPECTIVE COHORT; MUSCLE STRENGTH; MOTOR FUNCTION; NUSINERSEN; CHILDREN; SURVIVAL; ADULTS;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Infantile spinal muscular atrophy (SMA) type 2 is sometimes called intermediate SMA to indicate the disease severity. Generally, psychomotor development is normal until the age of 6 to 8 months, with the acquisition of a stable sitting position. The early signs are muscle weakness, mostly affecting the lower limbs, generalized hypotonia and areflexia. The consequences of motor neuron degeneration are functional and orthopaedic, respiratory, nutritional, socio-professional, and psychological. The implementation of standardized care (i.e., standard of care recommendations) has improved the quality of life and survival outcome of patients. The emergence of innovative therapies, some of which are now available, should further improve the clinical evolution of this disease. (C) 2020 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:18 / 22
页数:5
相关论文
共 50 条
  • [1] Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg-Welander disease)
    Salort-Campana, E.
    Quijano-Roy, S.
    ARCHIVES DE PEDIATRIE, 2020, 27 (07): : 23 - 28
  • [2] Assessment of Awareness of the Early Clinical Features of Spinal Muscular Atrophy (SMA) Amongst Pediatricians
    Curry, M.
    Cruz, R.
    Belter, L.
    Jarecki, J.
    ANNALS OF NEUROLOGY, 2019, 86 : S118 - S118
  • [3] Nutritional Analysis in Infants and Children with Spinal Muscular Atrophy (SMA) Type 2
    Poruk, Katherine E.
    Smart, Abby L.
    Reyna, Sandra P.
    Swoboda, Kathryn J.
    NEUROLOGY, 2011, 76 (09) : A515 - A515
  • [4] Proximal spinal muscular atrophy (SMA)
    Fujak, A.
    Wollinsky, K. H.
    Forst, R.
    ZEITSCHRIFT FUR ORTHOPADIE UND UNFALLCHIRURGIE, 2007, 145 (02): : 233 - 248
  • [5] Clinical features of spinal and bulbar muscular atrophy
    Rhodes, Lindsay E.
    Freeman, Brandi K.
    Auh, Sungyoung
    Kokkinis, Angela D.
    La Pean, Alison
    Chen, Cheunju
    Lehky, Tanya J.
    Shrader, Joseph A.
    Levy, Ellen W.
    Harris-Love, Michael
    Di Prospero, Nicholas A.
    Fischbeck, Kenneth H.
    BRAIN, 2009, 132 : 3242 - 3251
  • [6] Clinical features of spinal muscular atrophy in children
    Stanek, J.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 : S8 - S12
  • [7] Early Clinical Experience with Onasemnogene Abeparvovec in Spinal Muscular Atrophy (SMA) Type 2 Patients at a Single Center
    Matesanz, Susan
    Kichula, Elizabeth
    NEUROLOGY, 2020, 94 (15)
  • [8] The difference type and disease severity in a family with spinal muscular atrophy (SMA)
    Harahap, I. S. K.
    Thursina, C.
    Sadewa, A. H.
    Hapsara, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 279 - 279
  • [9] Spinal Muscular Atrophy (SMA) in the Therapeutic Era
    Gibbons, Melissa
    Stratton, Anne
    Parsons, Julie
    CURRENT GENETIC MEDICINE REPORTS, 2019, 7 (03) : 162 - 167
  • [10] Therapeutic approaches for spinal muscular atrophy (SMA)
    M Scoto
    R S Finkel
    E Mercuri
    F Muntoni
    Gene Therapy, 2017, 24 : 514 - 519